Unmet supportive care needs among head and neck cancer survivors beyond 5 years after diagnosis: a multinational cohort study.
AuteursJansen F, Eerenstein SE, Taylor KJ, Amdal CD, Bjordal K, Astrup GL, Herlofson BB, Duprez F, Gama RR, Jacinto AA, Hammerlid E, Scricciolo M, Fanetti G, Guntinas-Lichius O, Inhestern J, Dragan T, Fabian A, Boehm A, Wöhner U, Kiyota N, Krüger M, Bonomo P, Pinto M, Nuyts S, Silva JC, Stromberger C, Specenier P, Tramacere F, Bushnak A, Perotti P, Plath M, Paderno A, Stempler N, Kanellopoulou A, Singer S, Verdonck-de Leeuw IM
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registry.
AuteursDevos T, Deeren D, Theunissen K, Selleslag D, Bailly B, Havelange V, Lewalle P, Meers S, Benghiat FS, Gadisseur A, Granacher N, Vanstraelen G, Vellemans H, Becker A, Janssen M, Vrelust I, Lejeune M, Van de Velde A, Triffet A, Beck M, Sebti H, Mazure D
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial.
AuteursZilli T, Böhmer D, Roeder A, Lauffer D, Villafranca Iturre AE, Jové-Teixidó JJ, Supiot S, Latorzeff I, Dirix P, Otte FX, Francolini G, Roumeguère T, Simon JM, Fournier B, Fortpied C, Lara PC, Tombal B
Fertility Preservation Practices and Gastrointestinal (GI) Oncologist in Europe: A Pan-European study.
AuteursBen-Aharon I, Goshen-Lago T, Puccini A, Alsina M, Arnold D, Von-Larhoven H, Elme A, Buffart T, Fokter-Dovnik N, Sokop T, Obermanova R, Lordick F, Papamichael D, Sclafani F, Elez E, Taieb J
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis.
AuteursBregni G, Leurquin B, Giasafaki P, Takemura N, Kokudo N, Hasegawa K, Matsuyama Y, Nishioka Y, Aparicio T, Guimbaud R, Malicot KL, Tu D, O'Callaghan C, Lutz MP, Fontana E, Moehler M, Mauer ME, Sclafani F
Comparing [ <sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.
AuteursGarcía-Mosquera JJ, Pérez-García JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escrivá-de-Romaní S, Calvo Martínez L, Gebhart G, Kerrou K, Gion M, Antonarelli G, Santasusagna Canal S, Rodríguez-Morato J, Mina L, Sampayo-Cordero M, Llombart-Cussac A, Cortés J
